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Abstract. Endothelin-! (ET- ! ) is a potent vasoconstrictor peptide apparently in-
vo]ved in a number of vascular diseases in man. Nonetheless, its determination in 
biological sampies is difficult, and data on plasma or urine concentrations are con-
troversiaL We investigatcd different satnple preparation procedures as weIl as dif-
ferent radioimmunoassays for lheir inf)uence on ET-l measurement. Recovery of 
ET- I depended on Ihe extraction procedure, the type and size 01' the extraction 
columns and on the biulugical matrix itself. Incomplete removaJ of matrix com-
ponents by the extraclion leads to the formation of particulate maUer in the evap-
orated eluate. When dissolved in assay buffer, ET- I was found to be absorbed to 
and only partly released from these partieulates, so that it was not accessible for 
measurement in a radioimmunoassay. This was lhe ease for all extraction proce-
dures investigated except for that involving aeetie acid. HPLC analysis of spiked 
sam pies revealed that ET-I is in part degraded during extraction, most probably to 
Meth-sulphoxide ET-l. Dilution curves of synthetic pure ET-l standards from dif-
ferent suppliers. prepared either in plasma with subsequent extraction ur in assay 
buffer of the rcspcctive radioimmunoassay, resulted in considcrable differences in 
the measurcd values for ET-l-immunoreactivity. Every radioimmunoassay tcsted 
had a specific pallem of rccognizing different synthetic ET-I standards. In condu-
siol1 , the measurement of ET-l-immunoreactivity is strongly influenced by the ex-
perimental conditions of samplc prcparation as weil as by the radioimmunoassay 
employed. 
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Tntroduction 
Endolhelin-I (ET-l). whieh is the most potent vasoconstrietor peptide yet discov-
ercd, was originally isolated from culture supcrnatants of vascular endothelial 
cells [I]. Other mammalian endothelin isopeptides (cndothclin-2 and -3) have also 
been identified. but only ET- I is produccd by endothelial eells and seerns to oc-
eur in substantial amounts in human plasma. ET-l is apparcntly involved in a num-
ber ofvascular diseases in man. Elevated plasma levels of ET-I immunoreactivity 
(ET- I IR) have been detected in rnyocardial infarction [2]. vasospastic angina [31. 
hypertension [4. 5J. vasculitis [6J. subarachnoid haemonhage [7. 81. diabetes mel-
litus [9. 10]. and HlV infection [11 . 12]. 
In spite of these numerous stuilies, data on plasma endothel i t1 concentrations 
are hardly comparable and in part controversial [9. 10. 13-161. Although several 
radioimmunoassays (RIA) for the selective measurement of ET- l are avai Jable, re-
sults from different laboratories vary considerably. There is TIO consensus tcc;h-
niquc for the determination of this peptide, nor is there a generally accepted nor-
mal range in human plasma f9 . 131. Moreover, the antisera used in the respcctivc 
RIAs are sensiti ve to smal1 moclifications in the ehcmical structure uf ET-l, as 
shown by the (often considerable) cross-reaetivity of antisera bctwccn thc thrcc 
different bm structurally c10sely related endothelins. 
ET-L cannot be measured directly in biologicaJ fluids, but must bc purificd and 
concentrated by an extraction step. The chemical structurc of this 2 1-amino-aeid 
peptide includes two intraehain disulphide bonds (between positions 1-15 and 
3-11) as well as one methionine in position 7 [I]. Thereforc. it is vcry susceptible 
to chemical modification; reduetion with subsequent cleavage of the disulphide 
bonds as weil as oxidation of the methionine may Deellr during storage or pro-
cessing or sampies. depending on the assay condilions. Very little is known of the 
intluence of these degradation products on the binding affinity of ET-I to the anti-
bodies used in the respective radioimmunuassays. Moreover. matrix components 
Jike proteins, lipids, Of salts not removed by the extraction procedure may influ-
ence the binding of the antibodics to ET- L in a given radioimmunoassay. The pur-
pose of this sludy, therefore, was to evaLuate several extraetiol1 procedures de-
seribed in terms of recovery and stability uf ET- J, and to investigate several avail-
able RIAs regan.ling the immunoreaetivity of different synthetic ET-l preparations 
in order to establish a reliable method for the determination of ET- l in biological 
fluids. 
Materials and methods 
Reagents 
Synthetic purified ET- I was obtained from several suppliers: Serva (Heidelberg, Germany). 
Sigma (Deisenhofen, Germany), Peninsula (Belmont, Calif.) and NEN/Dupont (Dreieich, Gcr-
many). Synthctic ET-2 and ET-3 were purchased from Serva and 3_[ 1251] iodotyrosyl ET-I 
with a specific activity of 74 TBq/mmol and a radiochemical purity of > 90% from Amersham 
(Braunschwcig, Gcrmany) . 
Extraction was performed on silica-C18 cartridgcs (Scpak Cl8 Vac, 500 mg, WatersfMiJ-
Iipore, Eschborn, Germany) unless olherwise indicated. Other extraction cartridgcs tcsted wcrc 
Sepak C 18 c1assic 360 rng (Walers/Millipore) amI Bond-Elut Si-C 18 500 mg, 200 mg, 100 mg 
(Analytichem International. obtained from iet, f'rankrurt. Germany). Columns were used only 
onee. 
Five RlAs fur the measuremenl ofET-l that were eommereia11y available allhe time of thc 
sllldy wcrc cvaluatcd: Endothelin 1-21 spccific ['2 ~I]assay system (Amersham, Braunschweig, 
Gennany); Endolhelin-l , 2 RlA (Biomedica, Vienna. Austria); Endothelin-l, 2 [l25[] RIA Kit 
(NEN/Duponl, Dreieich, Germany); Endothelin RIA (Nichols Institute, Bad Nauheim, Ger-
rnany); Endnthelin-\ RIA (Peninsula Laboratories. Belmont. Calif.). Trifluoroacetic acid 
(TFA, I-mI sealed ampoules) and siliconizing reagent (Sigmacote) were purchased from 
Sigma (Deisenhofen, Germany). Phosphate-buffered saline (PBS) comained 0.145 M NaCI. 
0.018 M Na2HP04 and 0.010 M KaH2P04 • All other chemieals uscd were uf reagent grade ur 
better and obtained from Merck (Dannstadl, Gerrnany). 
SampIe colleclion 
For the collection of pooled human plasma, blood from hcalthy voluntccrs was drawn into 
EDTA-containing vacutainer tubes (Greiner, Frickenhausen, Gennany) without other addi-
tives, placed immediatelyon iee, and eentrifuged at 4°C. Plasma was pooled and stored unLiI 
use a1 -20°C. Cercbrospinal fluid (3 ml from cach) was collectcd after informcd conscnt from 
palienls undergoing spinal anaesthesia. Urine was collected rrorn three volunteers in thc rnOTll-
ing, ccntrifuged at 4"C and stored at _20°C. 
Extraction procedures 
Recovery of thc respecrive cxtraction proccdures was invcstigated by adding tu thc samplc 
prior tu extraction the 125I-labelled ET-l at dirferent conccntralions (0.4-120 [mol/mi) wilh or 
wiLhout non-Iabelled ET-l (400-40,0<Xl rrnol/ml). Radioactivity in the collected fractions was 
measured in a t2-well multi gamma counter (LR 2111, Rerthold, Wildbad, Germany). In order 
to study the fate of ET-l after extraction, the evaporated eluate wa<; dissolved in 0.5 ml of RlA 
buffer by repeated vigourous vortexing and left on ice for I h. The residual particulate matter 
and thc supcrnatant wcrc scparated by centrifugation. Tu the remaining pellet. another 0.5 m! 
of RIA buffer was addcd, and the proccdure was rcpcatcd with additional sonifieation. Each 
step was monitored for labelIed ET-l. All these experiments were done in triplieate. 
Stability of ET-I in the respective extraction procedures was determined by APLC analy-
sis. An aliquot of 10 J.lg of ET-\ (Serva, Heidelberg, Gennany) was added to a 2.5-ml plasma 
or urine sampie or to 0.2 ml of PBS and cxtracted as dcscribcd. Tbc c1uate was dried undcr rc-
duced pressure and redissolved in 100 j.tl PBS; 80 j.tl was injeclcd onto thc column. 
Thc capacity of thc rcspective extraction proccdures tu remove matrix components was 
judged by chemical analysis. The eluate was dissolved in 1 ml of distilled water, centrifuged 
and the supernatant investigated. Osmolarity was measured with a micro osmometer (3 MO, 
Advanced Instruments, obtained from Dinkelberg Lab0l1echnik. Neu-Uhu, Germany), total 
protein with Coomassic BriUiant Blue G 250 according to thc mcthod uf Bradford [17], Na and 
K on a flame photometer (Eppendorf, Hamburg, Gennany) and uric acid, crcatinine and urea 
on an automated c1inieal chemical analyser (Hitaehi 717, Buehringer Mannheim, Gennany). 
All these experiments were done in duplicate. Lipid content in the eluate was analysed by qualita-
tive thin-Iayer chromatography on silica gel 60 plates (200 x 200 x 0.25 mm, Merck, Darm-
stadt, Germany), using a standard one-dimensional system for the separation of simple lipid 
cla.sses with hexenlether/glacial acetic acid (80/20/2, v/v/v) as solvent. Plates were sprayed 
with 0.001 % 8-anilino-l-naphtalen sulphonate and lipids werc visualizcd as fluorcsccnt spots 
under UV light. Alternatively, plates were stained with iodine. 
The following extraction procedures were tested: 
I. Extraction with acetic acid (AA) [18]. Si-C18 cartridges were conditioned with one column 
reservoir volume (CV) of MeOH folLowed by one CV of water and one CV 10% AA, then 2.5 
ml of plasma or urine was diluted with an equal volume of 20% AA, centrifugcd (10 min, 
2,600 g) and applied to the columns. The sampIe was passed through at a flow rate determined 
by gravity (1 x g). Subsequently, culumns were washed with one CV 10% AA and excess AA 
was removed by applying reduced pressure. Columns were then washed with 2 CVs of ethyl 
acetate and dried under reduced pressurc. ET-l was eluted with 3 ml of MeOH/O.05 M ammo-
niumbicarbonate (80120, v/v) and the eluate dried in a centrifugal evaporator (Speedvac. Bach-
hüfer, Stuttgart, Gennany). 
2. Extraction with triHuoroacetic acid (TFA) [81. Si-CI8 cartridges were condilioned with 4 
ml of60% acetonitri[ein 0.1% TFA fo llowed by 20 ml ofO.[% TFA, then 2.5 m! ofplasmaor 
uril1e was diluted with an equal volume of 0.2% TFA, centri fuged (10 min, 2,600 g) and ap-
plied to the colunms. The sampie was passed through at a f10w rate determined by grav ity. 
Subsequently, columns were washed with 20 ml ofO.I% TFA and ET- l was eluted with 3 ml 
uf 60% acetonitrile in 0. 1 % TFA. Care was taken not to dry the columns during thi s procedurc. 
3. Extraction with ethano l (EtOH) [19]. Si-CI8 cartridges were conditioned with 5 ml of 
MeOH, 5 ml or water and 5 ml o f 4% AA, then 25 ml or plasma or urine was diluted wilh an 
equa l volume of 4% AA, centrifuged, applied 10 the columns and passed through ar a f10w rate 
determined by gravity. Columns were washed with 3 ml cf water and 3 ml o f 25% EtOH in wa-
ter. ET- I was eluted with 3 ml of 4% A/\ in 86('0 EIOH. 
4. Extraction with methanol (MeOH) [20]. Si-CI8 cartridgcs werc conditioned with 2 ml of 
MeOH followed by 3 ml of water. then 2.5 ml of plasma or uri ne was applied to the columns 
and passed lhrough al a flow rate detcrmined by gravity . Columns were washed with 4 ml of 
10% MeOH in water and ET-l was eluted with 4-6 ml of 85% MeOH in waler. 
Absorplioll o.{ ET-l on surfaces 
To invesligate the adherence of ET-I 10 various sllrfaces, 30 fmo l 12SI-ET-1 in 0.2 ml of PES 
o r in 0 .2 Oll of plasma was pipeued in triplicale into test tubes (5 ml) of bo rosilicate gl ass, 
polystyrol. polypropylene or siliconized polypropylene, or il1to 1.5-ml reaclion vials (Eppen-
dort, Hamburg. Gennany) or polypropylene-like HPLC micro vials (250 ).lJ , Weidmann Plas-
tik, Switzcrland). After standing for 30 min at room tcmpcrature the tubcs wcrc vigorously vor-
texed, spun down and the contenlS completely transferred to a new tube o r the same type. This 
procedure was repeated lwice, and in each step transferable and adherent radioacti vity was 
counted. In all other experiments with ET- L si liconized polypropylene tubes were used. 
Separation of EI'!, -2, -3 by HPLC 
The HPLC system consisLed of aL 6200 gradien L-controll ed pump. an AS 2000 autosampIer 
and a L 4000 variabl e-wave lenglh llV detector connected by a D 6000 intetface LO a D 6000 
Chromalography Data Station (all Merck-Hitachi, Darmstadt, Germany). Analysis was per-
formed on a CI8 reversed-phase column (250 x 4.6 mm, Superspher RP 18 cndcappcd 4).UTI, 
Merck, DarmSladl, Gcrmany), using a linear gradient from 10% acetonilrile in 0.1 % Ti-A Lo 
60% acctonitrile in 0.1 % TFA over 60 ruin, followcd by a purge gradient over 15 ruin to 100% 
acetonitrile in 0.1 % TPA and re-equilibralion ror 20 min. Plow rate was set 10 I ml/min, co l-
lImn temperature maintai ned at40" C and column eftl uent moni tored at 210 nm. 
Comparison of cOl1centration with immunoreactivity 0/ ET-l 
Standard curves (I-50 fmol/ml) werc prcparcd with different synthetic ET-l standa rds (see 
above), either in pooled human plasma followed by ext racl ion with AA, or directly in the as-
say butler of the respective RIA. These sampIes, logether with extracted blank plasma sam-
pies, were analysed in the fi ve RIAs eva luated. The added amount of ET-I was compared with 
the immunoreactivity measured . All these experiments were done in triplic3te, and in at least two 
different RlAs from the same supplicr. To investigatc the influencc of the different extraction 
procedures o n the RIA performance, plasma and urine samplcs with and withou t 10 fmol/ml 
ET-l (NEN) added (11 = 3 each) were extracted by the procedurcs described and analysed for 
immunoreactivity in the RIA obtained from NEN. 
Statistical analysis 
Statistical calculations were performed using the SPSS software package (SPSS/PC 4.0, 
Chicago, USA). Tests foe stati stical significance were calcul ated with Student's I-test and thc 
Chj-square test. 
Table 1. Comparison of the different extraction procedures. Recovery of 125I-Iabelled ET-l 
and residual components of the sampIe matrix eontained in the eluate are shown for the differ-
ent extraction procedures. Values are expressed as mean ± SD. CSF, cerebrospinal fluid 
Recovery uf Matrix rcsidues in the cluatc/obtaincd from 
!25I-ET-l a 2.5 ml sarnple 
(% 01' 10tal) 
Total protein Osmolarity pH 
(mg/I) mosmol/l) 
Extraclion from plasma wilh 
AA 88.4 ± 1.2 47.8 ± 4.7 11 ± I 5.5 ±O.I 
TFA 87.0 ± 0.2 1205.0 ± 33.8 8±1 2.0±O.1 
EtOH 84.9 ± 1.8 216.6 ± 17.5 o±o 5.2 ± 0.1 
MeOH 67.2 ± 2.0 164.9± 19.1 O±O 5.1 ±0.2 
Extraction "rom urine wiLh 
AA 98.6 ± 0.4 41.9 ± 3.4 7±1 5.2 ± 0.1 
TFA 98.0 ± 0.3 33.1 ± 4.9 56 ± 3 1.5 ±O.I 
EtOH 99.6 ± 0.1 17.5 ± 2.9 4±O 3.6 ± 0.2 
MeOH 92.1 ± 1.4 25.3 ± 5.8 2±1 4.4±0.1 
Extraction from CSF with 
AA 97.6 ± 0.2 36.7 ± 2.8 6±2 5.4±0.1 
Recovery of ET-l ill the different extractlon procedures 
Recovcry ratcs for the extraction uf 125T-labelled ET-l from plasma werc morc than 
65% of total radioaclivity, and for extraclion from urine or cerebrospinal Ouid 
more than 90% of the total, and were thus satisfactury for a11 procedures tested. 
However, extracLion elTiciency was significantly influenced by the melhod used 
(Table l). It was highest and nearly identieal for the methods involving AA or 
TFA, but signifieantly lower (P < 0.05) for the procedures involving EtOH or 
MeOH. For the extraction with MeOH in partieular, the elution volume of 3 ml 
llsed in the other extraction procedures only released 13% of ET-l, and up to 6 ml 
was necessary to remove ET-l completely from the columns. Recovery of ET-l 
fram urine or cerebrospinal fluid was almost camplete, independent of the type of 
extraction proeedure (Table 1). 
Matrix effect on the extraction efficiency 
Recovery was influenced by the matrix, and was significantly lower in plasma 
than in urine or cerebrospinal tltÜd. We found that 8-10% of ET-l was contained 
in the breakthrough of the plasma applied to the columns, whereas in urine or cere-
brospinal fluid only 1-2% of ET~l could be measured in this fraction. Moreover, 
addition of either TFA oe AA to a plasma sampie caused a mild protein precipita-
tion. After centrifugation there was a significant increase in the radioactivity mea-
sured in the resulting pellet, from 1.81 ± 0.05% to 2.80 ± 1.11% and 6.44 ± 0.94% 
or total if 2.5 ml water, 2.5 ml ur 5 ml of 0.2%TFA was addcd, respccIivcly. Vcry 
similar valucs were seen for acidification with AA (data not shown). 
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Fig.1. Recovery of ET-l depended on lhe colutnn type and size, but not on ET-l concentra-
tion. Extraction from plasma was performed on different C 18 CO)UffiIlS, indicated at the bottom 
of thc figurc. Thc [etters rcprcscnt thc different ET -1 conccntrations addcd: A. B, C.O.4, '12 ami 
120 fmollml 12Sj-labelied ET-I; D, E, F. 12 fmoVml 12' I-labellcd ET-I + 400, 4,000 and 40,000 
fmol/ml unlabelled ET-l. Mean ± SD is shown 
Other Jactors influencing recovery 
Recovery was dependent on the tlow rate used to pass the sampie through the col-
umn. It decreased significantly from 83,4 ± 2.6% of total at a f10w rate of I x g to 
71.5 ± 1,4% (n = 3 each) if the tlow rate was increased by applying reduced pres-
sure of 12 mmHg. Recovery of labelIed ET-I depended on the type and size of 
CI8 column tested (Fig.I). Sepak cartridges gave a slight but significantly (P < 
0.05) higher recovery than Bond-Elut of comparable size. Column sizes of less 
than 200 mg caused a significant loss of ET-l in the sampIe fraction. In contrast. 
thc extraetion recovery did not dcpcnd on thc ET-I concentration in the range 
testcd. For sampies containing 0,4, 12, and 120 fmol/ml 1251 ET-I, as weil as for 
sampies containing 12 fmol/ml 1251 ET-I and 400, 4,000, and 40,000 rmol/ml, un-
labe lied ET-I recoveries were not significantly different on Sepak 500 mg 
columns (Fig.l). Interestingly, the lower recoveries for Bond Elut 200 mg and 100 
mg columns were equally observed with sampies containing only 12 fmoi/ml 1251_ 
labelIed ET-I or 12 fmol/ml "'I-Iabelled ET-I + 40,000 fmol/ml unlabelled ET-l. 
Residual matrix components 
Thc cfficicncy of thc cxtraction proccdurcs to c1car the sampie from major plasma 
or urine components is shown in Table 1. For extraction of plasma, AA proved to 
be the most effective procedure to remove proteins and reduced the average pro-
tein content of plasma (70 g/I) to 50 mg/l in the eluate, In contrast, extraction with 
Table 2. Influcnce of urine composition on cxtraction. Recovery of '251-labclled ET -I and 
residual matrix componcnts after extraction with AA. SampIes 1-5 were preparcd rrom the 
same urine. 1,2 and 3 were adj usled tO pH 0.7, 5.5 and 9.2, respeclively; 4 and 5: addition 01' 
2.6 gfl creatinine, 50 g/l urea and 1 gll uric acid without (4) and with (5) addition of 50 gli al-
bumin. Values are given as mean ± SD. Addition or albumin redueed recovery significantly (P 
< 0.05) 
Extnlction Recovery 
from of 1251_ 
urine wilh ET-l 
acetic acid (ffo of total) 
I 
2 
3 
4 
95.0 ± 0.8 
91.7±0.1 
94.5 ± 0.3 
91.0 ± 0.8 
Total 
protein 
(mg/I) 
32.1 ± 1.8 
56.3 ± 1.6 
81.8 ± 3.4 
43.5 ± 2.6 
Osrno- pR 
lal'ity 
(mosmoll 
I) 
(J± 0 
8±3 
16 ± 0 
15 ± 4 
5.3 ±O.I 
5.5 ± 0.2 
5.4±0.1 
5.5±0.1 
Creatinine 
(mg/I) 
0.7 ± 0.2 
3.3 ± 0.6 
10.3 ± 0.9 
5.7 ± 0.8 
Urea 
(mgll) 
Uric acid 
(mg/I) 
20±43±2 
50± 3 354± 14 
90± 4 457± 12 
80± 6 611 ±27 
5 85.6 ± 0.6 71.4 ± 3.8 36 ± 2 5.2 ± 0.2 28.4 ± 1.1 280 ± II 147 ± 12 
TFA resulted in a residual protein content in the eluate of 1,200 mg/I, beside the 
insoluble particulates in which the presence of protein was also suspected. 
Thin-Iayer chromatography revealed thc presence of triglycerides and eholes' 
terol in the eluate after extraction of plasma wilh TFA or EtOH, and or triglyc-
erides only after extraction with MeOH. No lipids could be dctected after exlrac-
tion with AA. In urine, no lipids could be found with any of thc extraction proce-
dures. All extraction procedures, except for that of TFA, reduced the osmolarity of 
the urine tested (750 mosmol) to < 10 mosma!. The eluate was weekly acidic (pH 
5) except for extraction with TFA (pH 2). 
Blank plasma sampIes (n = 3 each) extracted with AA, EtOH and MeOH mea-
sured in the RTA of NEN yielded concentrations of 6.9 ± 1.2,5,9 ± 2. 1 and 16.2 ± 
0.3 fmol/ml, respectively. Parallel sampIes spiked to 10 fmol/ml resulted in mea-
sured values of 20.3 ± 0.6, 17.7 ± 5.9 and 49.0 ± 13.0, respectively. After extrac-
tion with TFA, howevcr, blank as weil a, spiked sampIes yielded values off the 
standard curvc, so that it was not possible to calculate conccntrations. There was a 
high non-specific binding 01' the tracer, must prubably due to matrix rcsidues, as bind-
ing of thc tracer in the sampIes (B/Bo) was highcr than in thc zero standard (Boff). 
Extract;on of urine samples 
As tested with AA, the pH of the sampIe (from 0.7 to 9.2) did not significantly in-
fluence either the pH of the eluate or the recovery (Table 2). In contrast, there was 
a slight increase of total protein, osmolarity, creatinine, UIea, and uric acid con-
centrations in the eluate with pH (P < 0.05). Modifying the matrix, simulating an 
extrcmely concentrated urine by addition or 2.6 g/l creatinine, 50 gll urea and I g/l 
uric acid, did not significantly affect the parameters measured as comparcd with 
the native urine, except for a slight increase of uric acid content, nor did it influ-
ence recovery of ET-l. In contrast, if 50 g/I albumin was additionally added, re-
covery was significantly (P < 0.05) reduced to the range of thai of plasma. Creati-
nine and urea content of the eluate were slightly (P < 0.05) increased, but pH, to-
tal protein and uric acid conccntration were not changed. 
Table 3. Absorption o f ET·) to panic ulatc material of the eluate. The cvaporated eluate from 
plasma or urine was dissolvcd in assay buffer and the supematant wa~ $eparated from the in· 
soluble particuLates. Recovery o f 125[· labe lled ET- I in the different fractions is g ivcn as % of 
total. Mcan ± SO is shown 
Extrac· Plasma Urine 
ti on 
pro· Supernatant Supematanl Res idual Supernatant Supernat<mt Residual 
cedure I 2 pellet I 2 pellet 
AA 99.60 ± 0.05 0.39 ± 0.12 0.00 ± 0.00 99.54 ± 0.21 0.3 1 ± 0.30 0.00 ± 0.00 
TFA 39.10 ± 3.47 14.25 ± 1.89 45.35 ± 2.55 36.24 ± 3. 12 14.44 ± 0.56 47.61 ± 4.5 1 
E,OH 75.53 ± 20.87 20.87 ± 3.78 0.37 ± 0.39 40.40 ± 4.60 44.82 ± 0. 10 7. 11 ± 2.45 
McOH 60.40 ± 9.39 16.30 ± 2.57 20.96 ± 5.41 77. 15 ± 1.34 18.89 ± 0.23 l.l l ± 0.19 
RecovelY 0/ E7: j / rom the eillate 
After evaporating U,e eluates, only small and easily soluble pellets were seen for 
extraction with AA, whcrcas for extraction with MeOH or EtOH larger pellets, 
and for extraction with TFA rather (arge pellets containing insoluble particulate 
mauer were obscrvcd. 
After separation of the supernatant from Ihe particulate fraction, ET-I was al-
most completely recovered in the ease of the extraction with AA, whereas betwecn 
25 % and 60% of ET- I was containcd in the partieulate fraetion after extraetion 
with EtOH, MeOH or TFA (Table 3). After a second alLempt to di ssolve the re-
maining patticulates by vigorous vortcxing followed by sonification, a substanlial 
amount of ET-I still remained fumly bound to the partieulate fraetion after extrac-
lion with MeOH or TFA. Very s imilar rcsults were obtained for urine sampIes 
(Table 3). The loss of ET- I into the pellet was consistent in at least two sets of ex-
periments. The percentage of ET-I bound to the pellet was somewhat variable 
within one extraclion procedure, ranging, for instance, from 45 .6% to 74.0% of the 
total for pellets obtained with TFA. 
Absorption 0/ ET- I to different sur/aces 
I25J-labelled ET- I adhered to the surface of routinel y used test tubes. Absorption 
(% of total , experiments in triplieate, eoeffieient of variation < 2%) was 61.9% for 
borosilieate gl ass, 61.8% for polystyrol , 65 .6% for polypropylene, 47.0% for 
polypropylene-like HPLC-mierovials and 55.1 % for Eppendorl" reaction vials. Sil-
ieonization 01" polypropylene tubes, or the addition of 0.2 ml of plasma prior to ET-
I redueed absorption to 2.9% and 4.2%, respectively. The average adherence to 
Gilson pipette Lips was 3.6%. If the non-adherent ET- .I was transfered 10 a new test 
tube, approximately the same amount of ET-I was found to be absorbed as in the 
first experiment (data not shown). 
High performance liquid chromatography 
The HPLC method describcd resulted in baseline separation of ET-I , -2, -3, and a 
degradation product of ET-l. Retention times in this system were constant, with a 
interassay coefficient of variation 01" 1.0% for ET-1. The method was sufficiently 
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precise to allow reliable quanlification 01" ET-I, with intra- and interassay coeffi-
eients of variation ur 3.6 and 6.1 % for injection of 5 ~ of ET-I und quantitation 
by peak area. Deteclion limit was O. I ~/injection , and the limit or lowest rehable 
quantification was I J.Iglinjection. The determination of ET- I was linear in the 
range tested from 1 to 20 l1g1injection. ET- I di!uted in PBS or water and injeeted 
directly onto the HPLC eluted in two peaks, a major one ut 40.1 min (peak I) und 
a smaller one at 37.2 min (peak 2) (Fig.2). The amount of peak 2 increased during 
storage of ET- I tor severa! weeks at 4Q C. Subsequent experiments showed tbat 
peak I could be eompletely cunverted 10 peak 2 by oxidation with Chloramin T 
(da!a not shown) . Therefore, peak 1 must probably represents native ET-l and 
peak 2 Meth-sulphoxide ET-l. 
When blank sampies extractcd from PBS or plasma were injected, only small 
interferences or none at all were seen at the elution times of ET-l and its degrada-
tion product, für al1 cxtraetion procedures. However, blank sampies extracted from 
urine yielded interfering peaks with areas in thc range or those of ET-l added in 
tbe case of extraction with MeOH or EtOH. Reeoveries of the extraction proce-
duces as tested with micromolar concentrations with unlabelled ET-l were signif-
icantly lower as tested 1251 ET-l in picomolar concentrations. Total (native and de-
graded ET-l) recoveries for extraction with AA, TFA, MeüH and EtüH were 
24.7%,6.7%, 80.2% and 64.9% from PBS, 70.2%, 59.8%, 64.6%, and 41.5% from 
plasma and 72.0%, 17.1 %,67.2% and 1.2% from urine, respectively. Control ex-
periments with 125I-labclled ET- I revealed that the low recovcrics of ET-l from 
PBS for the extractions wilh AA or TFA were due to absorption of ET-l onto the 
polypropylene wall of the column. Absorption was greatly increased (98.5% of lo-
tal) when it was extracted wilh AA over that with MeüH (6.9%) . Adherence un-
der acidie conditions was only observed when ET-I was added onto the columns 
in a prot.ein-free matrix, whercas recoveries [rom plasma in this expcriment wcrc 
87.3% and 8 1.5% for acidic and neutral conditions, rcspcctively. 
Degradation occurring during the extraction was calculated from the amaunt of 
deh'Tadation product quantitated by peak area, corrected by the recovery of the re-
spective extraction procedure and after subtracting the amount of degraded ET-I 
prescnt in the ET-l standard used to prepare thc sampies. Degradation was 22.2%, 
51.1%,1.2% and 2.2% of ET-I when extracted from PBS, but only 4.9%,3.1%, 
0.2%, lO.1 % of ET- l for extraction from plasma, wilh AA, TFA, MeOH and 
EtüH, respectively (Fig.2). In urine the amount of degradation was comparable to 
that of plasma (7.9%, 0.4% and 4.0% for AA, TFA, and MeüH) except for the ex-
tfaction with EtOH, when the low overall recovery did not allow ca1culation of 
degradation. Thus, degradation of ET-l was more pronounced für extractions in-
volving acids when investigated in a protein-free matrix, but plasma or urine seem 
to reduce the oxidative influence of acids on ET-l in the range of extraction pro-
cedures under neutral conditions. 
Immulloreactivity 0/ different ET- J slandards 
Different synthetic ET-I standards wcre checked for their immunorcactivity in the 
respectivc RTA. Dilution curves of ET-l proved to bc linear, and in most cascs 
there was a good congrucncy bctwccn thc curves obtained with sampies prepared 
in RIA buffer and the curves obtained with cxtractcd plasma sampies after sub-
tracting the blank plasma valuc. Howcvcr, each ET-l preparation had a very dif-
ferent immunorcaclivity, depending on the Rli\ useu, rcsulting in curves with dif-
ferent slopes (a1though usually without affecting the intercept). ET-I obtained 
horn Serva (Fig. 3a) had an extremely strong immunoreactivity in the RIA manu-
factured by Peninsula, with concentrations measured exceeding those expeeted up 
to tenfold. In cüntrast, in the RIAs from Biomedica, Amersham, NEN or Nichüls 
parallel sampies exhibited immunoreactivity only slightly higher, or even lower 
than expected. Für examplc, sampies spikcd to a concentration of 50 fmol/ml re-
sulted in measured eoncentrations of 13.4 ± 6.8, 32.3 ± 2.3, 34.6 ± 7.8, 92.5 ± 35.3 
and 337.6 ± 35.6 fmol/ml in thc RIAs from Amersham, NEN, Niehols, Biomedica 
and Peninsula, respectivcly. Intcrcstingly, for olher ET-l prcparations the relation-
ship between the RIAs was different. ET-I supplied by NEN (Fig.2b) exhibitcd 
immunorcactivity exceeding the concentration cxpcctcd in the RIAs produccd by 
Endothelin -1 Endothelin~ 1 (Imol/ml) (Imol/ml) 
1000 1000 
900 900 
BOO BOO 
" 
700 
" 
700 
~ ~0 0 0 0 600 ~ ~ ~ 600 ~ E E 
c c 
.Q bOO .Q 500 
7i 7i 
" " 
c c 400 ~ 400 ~ u u c c 0 0 / .U U 300 300 200 200 )-! 100 + 100 1 ! 
0 0 
0 25 50 75 100 0 25 50 75 100 
Endothelin-1 (fmol/ml) Endothel in- 1 (fmol/ml) 
a Concentration expected b Concentration expected 
Fig.3a, b. lrnmunoreactivity of synthelic ET- t from different suppliers. a ET - J obtained from 
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AA and measured wirh different radioimmunoassays. Assay obtained from (e ) Peninsula, 
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ter subtracling the respective blank plasma valut;!. Note thc different sealcs for x and y axes 
Biomedie •• nd Peninsula, but displayed the expeeted values in the RIAs of 
Niehols and NEN, and values lower than expeeted in the RTA from Amcrsham. 
S.mples spiked to 50 fmol/ml resulted in eoneentrations of29.6 ± 5.7, 49.2 ± 4.6, 
51.1 ± 14.1,217.4 ± 11.7 and 780.2 ± 150.8 fmol/ml in the RIAs of Amersham, 
NEN, Niehols, Peninsula and Biomediea, respeetively. ET-l obtained from Sigma 
was not recognized by most of the RIAs, resulling in dilution curves with a slope 
near zero, but in some instances there was a high background immunoreactivity 
resulting in • high intereept (20-50 fmol/ml) . However, in the RlA supplied by 
NEN, measured values were approximately 80% of the concentrations expected. 
Performance 0/ the radioimmunoassays 
The overaU (including the impreeision of the extraetion) intra-assay eoeffieients of 
variation for sampies extraeted with AA from blank plasma (11 = 4) were 2.9%, 
4.4%,15.7%, 41.2% and 55.1 % for RIAs from Nieho!s, NEN, Amersham, Bio-
medica and Peninsula, respectively. Thc mean overall intra-assay coefficients of 
variation of a dilution curve from 50 to 6.25 fmoi/ml (ET-l from Serva, four eon-
eentrations, each Il = 4) for sampies extraeted from plasma were 7.2%, Il.l %, 
11.5%, 20.2% and 22. 1 %, and for sampies prcpared in the respeetive RTA huffer 
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were 3.9%, 4.2%, 8.4%, 19.8% 2 1.8% for RIAs from NEN, Nichols, Peninsula, 
Biomedica and Amersham, respectively. For the dilution curves prepared with ET-
I from olher suppliers similar values were found (dala not shown). 
The performance of thc RIA obtained from NEN was further cvaluated in a 
larger serics over aperiod of 6 months. The overall intra-assay coefficicnts of vari-
aLion for a dilution curvc prcparcd in plasma with concentrations o[ 50, 25, 12.5, 
and 6.25 fmol/ml 01' ET- l from NEN added (n = 6 each) were 5.3%, 2.8%. 2.6% 
and 4.9%, and the overall interassay coefficicnls of variation (n = 10 each) for par-
allel sampies werc 9.4%, 10.0%, 16.2% and 13.4%, respeclively. 
Scnsitivity of the assay was 0.1 fmol/tube. The mean (n = 101 level of lowest 
rcliable quantification (defined as sampies with a tracer displacement < mean 
tracer displaccmenL of the zero standard - 3 SO) was 0.52 fmol/ml. Determination 
of ET-l was linear from 1 to 50 [mol/mI. Howcver, at higher conccntrations we 
observed a considerable nattening or even plateau of thc dilution curvC$ preparcd 
with ET-l frorn NEN, sometimes with lower values for nominal concenlTalions of 
100 fmol/ml as compared with 50 fmol/ml (Fig. 4 a1. This was reproducible in sev-
eral RIAs from different lots and could be observed with extracted plasma sampies 
as weil as with sampies diluted directly in RIA butler. ET- l from other suppliers, 
however, yielded linear curvcs up to 100 fmol/mL In the low range of the assay (I 
to 10 fmoUml) we found a good congruency between vaJues mcasured and values 
expected (Fig.4b). 
Discussion 
Exlr3ction recovery uf ET-L from biological sampIes and the results uf ET- I im-
munoreactivity measurcments are strongly influenccd by the experimental condl-
tions. Ahhough most extraction procedures investigatcd yielded sufficicnt recov-
ery of ET-I, important differences between the methods could be observed. Ex-
traetions based on aeidic eonditions resu1ted in highcr and more eonstant recover-
ies than the Olle based on neuu'al conditions. Moreover, differences in the effi-
ciency of clearing the eluate from matrix components were seen. The method 
based on TFA resulted in the highest residual protein content after extraction of 
plasma and the highest residual osmolarity after extraction of urine, indicating an 
incomplete removal of matrix components. Residual lipids could be detected in 
the eluate after extraction of plasma for all procedures investigated except that of 
AA, where the additional lipoph-ilic washing step with ethylacetate was able to re-
move plasma lipids efficiently without eluting ET-I. Residual protein content led 
to thc formation of insoluble particulate material after evaporation of the eluate. 
lntereslingly, in all extraction proccdures, except in that 01' AA, ET-l was absorbed 
to these particulates in a considcrable amoußL. After di ssolving thc dried eluate in 
assay buffer, even supported by sonification, ET-J was only partly rcleased into 
the supernatant. As only soluble ET-l is acccssible lO the antisera uf the RIA, this 
phenomenon may greatly intluellce the results of ET-l measurement. Moreover, 
we could demonstrate that matrix components not removed by the extraction can 
intluence the pelfur.mance of the RIA. High proteiD content was shown to increase 
the non-spccific binding of the tracer to thc antibody, making the measuremcnt 
less sensitive for low concentrations of ET-l. 
Recovery of ET-l was also influenced by the sampie matrix. We found a lower 
recovery of ET-l from plasma than from urine or cerebrospinal fluid for all ex-
traction procedures. This, together with the finding that the loss of ET-l from 
plasma was contained in the breakthrough of the plasma fraction, suggests that ET-
I is in part bound 10 plasma proteins with a higher affinity as to the stationary 
phase of the extraction columns. This hypothesis is funher supported by the fact 
that addition of albumin to urine reduccd recovery or ET-] to the range or plasma. 
Furthermore, this indicates that albumin rnight be lhe main binding protein for ET-
I in plasma. The exact nature of ET-I binding, huwever, remains to be established. 
Small moleeules like peptides or drugs are usually bound to plasma proteins by 
weak hydrophobie interaetions and are almost completely released by CIS column 
extraction. However, for bilirubin, it could be shown that the fraction of o-bilim-
bin is covalently Iinked to plasma proteins [21). In this connection il is of interesl 
to note that aeidie protein prceipitation eaused a loss of ET- J into the pellet and 
tbat the amount of ET-I in the pellet was dependent on the amount uf protein pre-
cipitated. 
The two types of CI8 columns tested differed only slightly regarding recovery 
of ET-l. Recovery uf ET-I did not depend on ET-I coneentration, even if a mure 
than 3,OOO-fold excess of unlabelled ET-I was added, indicating a high eapacity of 
the columns to bind ET-l. Furtbermore, recovery of ET-l did not signiftcantly 
change with column sizes betwe.en 500 and 200 mg. if care was taken to optimize 
the volume of the elution buffer. However, column slzcs of less than 200 mg 
caused a signiftcant loss of ET-l inlo tbe brcakthrough of the plasma fraction , re-
gardless of the amount uf ET-l added. This ftnding suggests that CI8 columns 
have a high binding capacity for ET-I, but a limitcd one tor plasma components. 
The latter may occupy binding sites of the stationary phase, thereby inhibiting fur-
ther binding of ET-I. Re-evaluation of recovery, thercfore, is recommendcd if one 
is decreasing column size or increasing plasma sampIe size. 
Like most small peptides, ET-I contained in a protein-free matrix was absorbed 
on all of the tested surfaces. Adherence was greatly increased by aeidic conditions. 
However, absorbtion onto polypropylene was completely prevented by siliconiza-
tion, or by prior addition of plasma. Even the small residual protein content of thc 
eluate after extraction with AA was sufficient to block adherence to the poly-
propylene tubes. Therefore, for handling biological sampIes siliconization of test 
tubes seems not to be required. 
ET-I concentrations in biological sampies are far below the detection lirnit of 
UV-absorption, rendering direct HPLC analysis impossible. However, the method 
described allowed reliable quantiftcation of ET-I added in micromolar concentra-
tions to biological samplcs. We invcstigated sampIes prepared in PBS, plasma or 
urine for recovery and for degradation products after cxtractioo. The degraded 
form, most probably, represents Metb-sulphoxide ET-l, a1tbough definitive confir-
mation by mass-spectromctry could not be performed. Extraction with AA or TFA 
led to a markedly higher degradation as compared with extraction with MeOH or 
EtOH in a protein-rree matrix. However, when it was extractcd 1'rom plasma or 
urine, degradation 01' ET-l by acidic conditions was strongly reduced to less than 
5% of total. This was comparable to that observed under neutral conditions. 
Recovery of ET-l from plasma was lower than in the experiments with the la-
belled peptide. This might be caused by the IOO-told higher concentration of ET-
I used in these experiments as compared with the highest amount of unlabelled 
ET-I added in the recovery assays with "'I-Iabelled ET-I. Moreover, absorption of 
ET-I to the particulate matter in the eluate for same extraction procedures may 
also greatly reduce recovery measured from the supernatant, as compared with to-
tal recovery measured with 125I-labclled ET-l. Recovery from urine was in the 
range of that for plasma for extraction with AA or MeOH. For extraction with 
TFA or ElOH, only a smaU amount of ET-I addcd could bc dctected. In part this 
might be due to interfering peaks at the elution time of ET-I and Melh-sulphoxidc 
ET-l, making quantincation by subtracting the blank va]ue unrcliable. 
Each of every RIA evaluated showed a characteristic pattern in responding to 
different synthetic ET-l standards. In addition, a high variability in tbe immunore-
activity oI the different ET-I preparations was observed. This tjnding had beeil uo-
cxpected in as much as al1 ET-l standards uscd were produeed by peptide synthe-
sis and lyophilized from a volatile buffer. According to the manufacturers ' infor-
mation, the protein content of these preparations was at least over &0%, and the 
protein was eonflrmed as pure ET-l to greater than 98% by HPLC analysis. There-
fore, the considerable diffcrenees observed in their immunoreaetivities remain to 
be elueidated. One possible explanation would be that ehemieal modi fieation s of 
thc peptide during storage or handling, spccific for a given prcparation, leads to 
the formation of degraded peptide. This, even in small amounts, by virtue of a high 
cross reactivity with the antibody used in the radioimmunoassay, would influencc 
ET-l immunorcactivily determinations. 
The RIA obtained from NEN was charaeterized by the best congrueney be-
tween the umount o[ ET-l added and the measured concentrations for most of the 
ET-l standards tested. This might be due to the fact that in the RIA from NEN a 
monoclonal mouse antibody was used, whereas all other kits were based on poly-
clon al rabbit antiserum. Moreover, this assay yielded the smallest coefficients of 
variation within day, as weil as from day to day, for blank plasma sampies and for 
spiked sampies up to 50 fmol/mI . At higher concentrations there was an unex-
plained flattening of dilution eurves prepared with ET-I from NEN whieh eould 
not be observed with ET-I from other suppliers. Besides this , we found this assay 
pcrforming better for physiological concentrations of ET-l in plasma, cerebro-
spinal fluid or urine in terms of the cocfficients of variation as wen as of the cor-
respondence hetween expected and TU.easured va lues. 
In conclusion, our study c1early demonstrates that ET-l determination in bio-
log ical sampies is strong ly dependent on the assay conditions. The extraction pro-
cedurcs vary with respcct to recovery of soluble ET-l and removal of matrix com-
ponents, and both factors have impact on ET-J immunoreacdvity measurement. 
From our data we can conclude that the extraction proccdure involving AA is the 
most efficicnt. becausc uf the high and constant recovery of ET-l and thc low ma-
trix interference. The oxidative influence of AA on ET-l seems lo be prevented by 
the protein content of biologieal sampies. The RIAs evaluated showed striking dif-
ferences in the measurement of ET-I-immunoreactivity for synthetic ET-l from 
different suppliers. The RIA from NEN gave the best approximation betwccn 
added ET-l concentrations and measured vailles. In our hands, the assay per-
formed with good precision over more than a year and proved to be suitable for the 
reUable measurement of ET-l 1n plasma and urine in patient sampies [111-
The study ofET-l has become mOfC and more widespread in clinical research. 
With the availability ofET-l antagonists in the near future, precise ET-l meaSllre-
mcnt may be a crucial prerequisite for lherapeulic decisions. Therefore, there is an 
urgent need for standardization in this field, and quality eontral and quality-assur-
am;e programmes should bc an jmportant research issue for future work on en-
dothelins. 
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